This is a significant achievement for the Company and demonstrates the breadth of Immatics’ innovation power and the quality of its science.
| Munich, Germany – 3 January 2019 – Immatics, a leading company in the field of cancer immunotherapy, today announced that the United States Patent and Trademark Office has issued the 100th patent to Immatics. This is a significant achievement for the Company and demonstrates the breadth of Immatics’ innovation power and the quality of its science. Immatics’ strong patent portfolio enables the Company to develop its pipeline of cancer immunotherapies, to protect Immatics’ innovations and to safeguard the Company’s technology investments. Immatics’ 100th patent (US Patent No 10,143,731) is directed against a peptide target discovered using the Company’s XPRESIDENT® technology. The peptides identified by XPRESIDENT® are presented by human leucocyte antigen (HLA) receptors on the surface of cells and are central to developing a range of novel powerful immunotherapies. “Since its inception, Immatics has put a key focus on the development of its Intellectual Property estate, in order to protect our technology innovations in this highly competitive field”, said Dr. Rainer Kramer, CBO of Immatics. “Being awarded the 100th issued US patent in the Life Science industry is fantastic, proving that our inventions move Immatics further to the forefront of the highly competitive field of Immunotherapy development.” Immatics’ patenting strategy ensures broad protection of the Company’s products, technologies and methods while still meeting the patentability requirements in the USA in a fast-paced environment. |
| - ENDS - |
| Notes To Editors About Immatics Immatics’ pipeline includes T-cell therapy programs based on the proprietary ACTolog®, ACTengine® and ACTallo® approaches, which are developed in collaboration through Immatics US with University of Texas MD Anderson Cancer Center and co-funded by the Cancer Prevention and Research Institute of Texas (CPRIT), and several bispecific TCR and antibody molecules. Operating from Tuebingen, Munich and Houston, the Company has recognized that novel, better and safer targets are the key to developing future cancer immunotherapies and it is Immatics’ mission to deliver the power of T cells to cancer patients. For regular updates about Immatics, visit www.immatics.com. |
| Issued for and on behalf of Immatics by Instinctif Partners. |
| Immatics Biotechnologies GmbH | Instinctif Partners |
